Galmed Pharmaceuticals Ltd. buy Morgan Stanley
Start price
02.12.24
/
50%
€6.40
Target price
02.12.25
€95.17
Performance (%)
-
End price
03.12.25
-
Summary
This prediction was cancelled by the user.Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Galmed Pharmaceuticals Ltd. | - | - | - |
| iShares Core DAX® | 0.191% | 4.892% | 22.046% |
| iShares Nasdaq 100 | -0.614% | 2.901% | 7.804% |
| iShares Nikkei 225® | 0.599% | 7.404% | 22.218% |
| iShares S&P 500 | -0.036% | 3.489% | 4.833% |
Comments by Morgan_Stanley for this prediction
In the thread Galmed Pharmaceuticals Ltd. diskutieren
Globus Medical, Inc. (NYSE: GMED) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $100.00 price target on the stock, up previously from $83.00.
Ratings data for GMED provided by MarketBeat
In the thread Trading Galmed Pharmaceuticals Ltd.
Die von Morgan_Stanley gewählte maximale Laufzeit wurde überschritten
Current prediction by Morgan_Stanley for Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd.
Start price
Target price
Perf. (%)
€6.40
15.07.25
15.07.25
€58.28
15.07.26
15.07.26
-
19.09.24
19.09.24
